Janis M Miyasaki

Summary

Affiliation: University Health Network
Country: Canada

Publications

  1. doi request reprint Palliative care in Parkinson's disease
    Janis M Miyasaki
    The Movement Disorders Centre, The Edmond J Safra Program in Parkinson s Disease, University of Toronto, Toronto, Canada
    Curr Neurol Neurosci Rep 13:367. 2013
  2. doi request reprint Palliative care for advanced Parkinson disease: an interdisciplinary clinic and new scale, the ESAS-PD
    Janis M Miyasaki
    The Palliative Program for Parkinson Disease and Related Disorders, The Morton and Gloria Shulman Movement Disorders Centre, Toronto Western Hospital, University of Toronto, Canada
    Parkinsonism Relat Disord 18:S6-9. 2012
  3. doi request reprint Chorea caused by toxins
    Janis M Miyasaki
    Morton and Gloria Shulman Movement Disorders Centre, Krembil Neuroscience Centre, University Health Network, University of Toronto, Toronto, Canada
    Handb Clin Neurol 100:335-46. 2011
  4. doi request reprint Evidence-based initiation of dopaminergic therapy in Parkinson's disease
    Janis M Miyasaki
    The Movement Disorders Centre, Toronto Western Hospital, University Health Network, Toronto, ON, Canada
    J Neurol 257:S309-13. 2010
  5. doi request reprint Using evidence-based medicine in neurology
    Janis M Miyasaki
    The Morton and Gloria Shulman Movement Disorders Centre, Toronto Western Hospital, University of Toronto, 399 Bathurst Street, 7 McL, Toronto, ON M5T 2S8, Canada
    Neurol Clin 28:489-503. 2010
  6. ncbi request reprint New practice parameters in Parkinson's disease
    Janis M Miyasaki
    Movement Disorders Centre, Toronto, ON, Canada
    Nat Clin Pract Neurol 2:638-9. 2006
  7. doi request reprint Impulse control and related disorders in Parkinson's disease: review
    Shen Yang Lim
    Movement Disorders Centre, Toronto Western Hospital, Toronto, Ontario, Canada
    Ann N Y Acad Sci 1142:85-107. 2008
  8. ncbi request reprint Levodopa response in long-term bilateral subthalamic stimulation for Parkinson's disease
    Panida Piboolnurak
    Movement Disorders Center, Division of Neurology, University of Toronto, Toronto Western Hospital, Toronto, Ontario, Canada
    Mov Disord 22:990-7. 2007
  9. ncbi request reprint Punding prevalence in Parkinson's disease
    Janis M Miyasaki
    Movement Disorders Centre, Toronto Western Hospital, University Health Network, Krembil Neuroscience Centre, University of Toronto, Toronto, Canada
    Mov Disord 22:1179-81. 2007
  10. pmc Dopamine agonists diminish value sensitivity of the orbitofrontal cortex: a trigger for pathological gambling in Parkinson's disease?
    Thilo van Eimeren
    Division of Brain, Imaging and Behaviour Systems Neuroscience, BIB SN, Toronto Western Research Institute, University of Toronto, Toronto, ON, Canada
    Neuropsychopharmacology 34:2758-66. 2009

Collaborators

Detail Information

Publications11

  1. doi request reprint Palliative care in Parkinson's disease
    Janis M Miyasaki
    The Movement Disorders Centre, The Edmond J Safra Program in Parkinson s Disease, University of Toronto, Toronto, Canada
    Curr Neurol Neurosci Rep 13:367. 2013
    ..Adopting palliative care principles will allow neurologists to fulfill the needs of PD patients in advanced stages to the end of life...
  2. doi request reprint Palliative care for advanced Parkinson disease: an interdisciplinary clinic and new scale, the ESAS-PD
    Janis M Miyasaki
    The Palliative Program for Parkinson Disease and Related Disorders, The Morton and Gloria Shulman Movement Disorders Centre, Toronto Western Hospital, University of Toronto, Canada
    Parkinsonism Relat Disord 18:S6-9. 2012
    ..Palliative care concepts were applied to a group of advanced Parkinson disease (PD) patients in a dedicated Palliative Care Clinic...
  3. doi request reprint Chorea caused by toxins
    Janis M Miyasaki
    Morton and Gloria Shulman Movement Disorders Centre, Krembil Neuroscience Centre, University Health Network, University of Toronto, Toronto, Canada
    Handb Clin Neurol 100:335-46. 2011
    ..The following chapter will discuss toxins associated with chorea and the presumed pathophysiology underlying the movement disorders in these case series...
  4. doi request reprint Evidence-based initiation of dopaminergic therapy in Parkinson's disease
    Janis M Miyasaki
    The Movement Disorders Centre, Toronto Western Hospital, University Health Network, Toronto, ON, Canada
    J Neurol 257:S309-13. 2010
    ..However, side effects may change the risk-benefit of dopamine agonist first strategies. In the following, the evidence for levodopa and dopamine agonists as initial monotherapy for PD is examined...
  5. doi request reprint Using evidence-based medicine in neurology
    Janis M Miyasaki
    The Morton and Gloria Shulman Movement Disorders Centre, Toronto Western Hospital, University of Toronto, 399 Bathurst Street, 7 McL, Toronto, ON M5T 2S8, Canada
    Neurol Clin 28:489-503. 2010
    ..This article covers the basics of critical appraisal and an introduction to statistics that will help clinicians, patients, and policymakers make sense of scientific evidence...
  6. ncbi request reprint New practice parameters in Parkinson's disease
    Janis M Miyasaki
    Movement Disorders Centre, Toronto, ON, Canada
    Nat Clin Pract Neurol 2:638-9. 2006
  7. doi request reprint Impulse control and related disorders in Parkinson's disease: review
    Shen Yang Lim
    Movement Disorders Centre, Toronto Western Hospital, Toronto, Ontario, Canada
    Ann N Y Acad Sci 1142:85-107. 2008
    ..Practicing neurologists must understand these problems to limit potential harm. In this article, we summarize current knowledge regarding these behavioral disorders, including phenomenology, epidemiology, pathophysiology, and treatment...
  8. ncbi request reprint Levodopa response in long-term bilateral subthalamic stimulation for Parkinson's disease
    Panida Piboolnurak
    Movement Disorders Center, Division of Neurology, University of Toronto, Toronto Western Hospital, Toronto, Ontario, Canada
    Mov Disord 22:990-7. 2007
    ..1% at 3 years and 19.2% at 5 years). Anti-PD drugs were significantly reduced by 47.9% at 3 years and 39.8% at 5 years. However, the magnitude of the preoperative response to levodopa did not predict DBS benefit at 3 and 5 years...
  9. ncbi request reprint Punding prevalence in Parkinson's disease
    Janis M Miyasaki
    Movement Disorders Centre, Toronto Western Hospital, University Health Network, Krembil Neuroscience Centre, University of Toronto, Toronto, Canada
    Mov Disord 22:1179-81. 2007
    ..4%) in contrast with previous reports of 14%. Despite the low incidence, this behavior is disruptive and should be carefully elicited by physicians caring for Parkinson's disease patients...
  10. pmc Dopamine agonists diminish value sensitivity of the orbitofrontal cortex: a trigger for pathological gambling in Parkinson's disease?
    Thilo van Eimeren
    Division of Brain, Imaging and Behaviour Systems Neuroscience, BIB SN, Toronto Western Research Institute, University of Toronto, Toronto, ON, Canada
    Neuropsychopharmacology 34:2758-66. 2009
    ..Our findings raise the question of whether pathological gambling may in part stem from an impaired capacity of the OFC to guide behavior when facing negative consequences...
  11. ncbi request reprint Factors associated with dopaminergic drug-related pathological gambling in Parkinson disease
    Valerie Voon
    National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892, USA
    Arch Neurol 64:212-6. 2007
    ..To evaluate factors associated with pathological gambling (PG) in Parkinson disease (PD)...